Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile

Science Translational Medicine

Volumn 4, Issue 128, 2012, Pages

  Hrkach, Jeffrey ^a   Von Hoff, Daniel ^b   Ali, Mir Mukkaram ^a   Andrianova, Elizaveta ^a   Auer, Jason ^a   Campbell, Tarikh ^a   De Witt, David ^a   Figa, Michael ^a   Figueiredo, Maria ^a   Horhota, Allen ^a   Low, Susan ^a   McDonnell, Kevin ^a   Peeke, Erick ^a   Retnarajan, Beadle ^a   Sabnis, Abhimanyu ^a   Schnipper, Edward ^a   Song, Jeffrey J ^a   Song, Young Ho ^a   Summa, Jason ^a   Tompsett, Douglas ^a   Troiano, Greg ^a   Hoven, Tina Van Geen ^a   Wright, Jim ^a   LoRusso, Patricia ^c   Kantoff, Philip W ^d   Bander, Neil H ^e   Sweeney, Christopher ^d   Farokhzad, Omid C ^f   Langer, Robert ^g   Zale, Stephen ^a   more..

^a BIND Biosciences Inc   (United States)

^b HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Massachusetts Institute of Technology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; NANOPARTICLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TUMOR ANTIGEN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; POLYMER; TAXOID;

ANAPHYLAXIS; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER INHIBITION; COMBINATORIAL LIBRARY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERABILITY; HUMAN; HYDROPHILICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SINGLE DRUG DOSE; SOLID TUMOR; ANIMAL; CHEMISTRY; DRUG SCREENING; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; NANOPARTICLES; POLYMERS; RATS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858665432     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003651     Document Type: Article

References (48)

1. K. Strebhardt, A. Ullrich, Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473-480 (2008).
2. B. A. Chabner, T. G. Roberts Jr., Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65-72 (2005).
3. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
4. C. Sawyers, Targeted cancer therapy. Nature 432, 294-297 (2004).
5. M. R. Green, Targeting targeted therapy. N. Engl. J. Med. 350, 2191-2193 (2004).
6. O. C. Farokhzad, R. Langer, Impact of nanotechnology on drug delivery. ACS Nano 3, 16-20 (2009).
7. J. Shi, Z. Xiao, N. Kamaly, O. C. Farokhzad, Self-assembled targeted nanoparticles: Evolution of technologies and bench to bedside translation. Acc. Chem. Res. 44, 1123-1134 (2011).
8. T. D. Heath, R. T. Fraley, D. Papahdjopoulos, Antibody targeting of liposomes: Cell specificity obtained by conjugation of F(ab?)2 to vesicle surface. Science 210, 539-541 (1980).
9. J. S. Murday, R. W. Siegel, J. Stein, J. F. Wright, Translational nanomedicine: Status assessment and opportunities. Nanomedicine 5, 251-273 (2009).
10. L. Y. Chou, K. Ming, W. C. Chan, Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 40, 233-245 (2011).
11. F. Gu, L. Zhang, B. A. Teply, N. Mann, A. Wang, A. F. Radovic-Moreno, R. Langer, O. C. Farokhzad, Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl. Acad. Sci. U.S.A. 105, 2586-2591 (2008).
12. O. C. Farokhzad, J. Cheng, B. A. Teply, I. Sherifi, S. Jon, P. W. Kantoff, J. P. Richie, R. Langer, Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 6315-6320 (2006).
13. S. D. Perrault, C. Walkey, T. Jennings, H. C. Fischer, W. C. Chan, Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9, 1909-1915 (2009).
14. C. Salvador-Morales, L. Zhang, R. Langer, O. C. Farokhzad, Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 30, 2231-2240 (2009).
15. J. Cheng, B. A. Teply, I. Sherifi, J. Sung, G. Luther, F. X. Gu, E. Levy-Nissenbaum, A. F. Radovic-Moreno, R. Langer, O. C. Farokhzad, Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869-876 (2007).
16. A. E. Nel, L. Mädler, D. Velegol, T. Xia, E. M. Hoek, P. Somasundaran, F. Klaessig, V. Castranova, M. Thompson, Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8, 543-557 (2009).
17. D. J. Siegwart, K. A. Whitehead, L. Nuhn, G. Sahay, H. Cheng, S. Jiang, M. Ma, A. Lytton-Jean, A. Vegas, P. Fenton, C. G. Levins, K. T. Love, H. Lee, C. Cortez, S. P. Collins, Y. F. Li, J. Jang, W. Querbes, C. Zurenko, T. Novobrantseva, R. Langer, D. G. Anderson, Combinatorial synthesis of chemically diverse core-shell nanoparticles for intracellular delivery. Proc. Natl. Acad. Sci. U.S.A. 108, 12996-13001 (2011).
18. R. Weissleder, K. Kelly, E. Y. Sun, T. Shtatland, L. Josephson, Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418-1423 (2005).
19. H. Wang, K. Liu, K. J. Chen, Y. Lu, S. Wang, W. Y. Lin, F. Guo, K. Kamei, Y. C. Chen, M. Ohashi, M. Wang, M. A. Garcia, X. Z. Zhao, C. K. Shen, H. R. Tseng, A rapid pathway toward a superb gene delivery system: Programming structural and functional diversity into a supramolecular nanoparticle library. ACS Nano 4, 6235-6243 (2010).
20. K. T. Love, K. P. Mahon, C. G. Levins, K. A. Whitehead, W. Querbes, J. R. Dorkin, J. Qin, W. Cantley, L. L. Qin, T. Racie, M. Frank-Kamenetsky, K. N. Yip, R. Alvarez, D. W. Sah, A. de Fougerolles, K. Fitzgerald, V. Koteliansky, A. Akinc, R. Langer, D. G. Anderson, Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. U.S.A. 107, 1864-1869 (2010).
21. A. Akinc, A. Zumbuehl, M. Goldberg, E. S. Leshchiner, V. Busini, N. Hossain, S. A. Bacallado, D. N. Nguyen, J. Fuller, R. Alvarez, A. Borodovsky, T. Borland, R. Constien, A. de Fougerolles, J. R. Dorkin, K. Narayanannair Jayaprakash, M. Jayaraman, M. John, V. Koteliansky, M. Manoharan, L. Nechev, J. Qin, T. Racie, D. Raitcheva, K. G. Rajeev, D. W. Sah, J. Soutschek, I. Toudjarska, H. P. Vornlocher, T. S. Zimmermann, R. Langer, D. G. Anderson, A combinatorial library of lipidlike materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561-569 (2008).
22. A. K. Rajasekaran, G. Anilkumar, J. J. Christiansen, Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol. Cell Physiol. 288, C975-C981 (2005).
23. Taxotere Prescribing Information (sanofi-aventis U.S. LLC, Bridgewater, NJ, 2010).
24. K. Avgoustakis, Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: Preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 1, 321-333 (2004).
25. F. Alexis, E. Pridgen, L. K. Molnar, O. C. Farokhzad, Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008).
26. K. P. Maresca, S. M. Hillier, F. J. Femia, D. Keith, C. Barone, J. L. Joyal, C. N. Zimmerman, A. P. Kozikowski, J. A. Barrett, W. C. Eckelman, J. W. Babich, A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J. Med. Chem. 52, 347-357 (2009).
27. S. M. Hillier, K. P. Maresca, F. J. Femia, J. C. Marquis, C. A. Foss, N. Nguyen, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman, M. G. Pomper, J. L. Joyal, J. W. Babich, Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 69, 6932-6940 (2009).
28. S. S. Chandran, S. R. Banerjee, R. C. Mease, M. G. Pomper, S. R. Denmeade, Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol. Ther. 7, 974-982 (2008).
29. T. Riley, C. R. Heald, S. Stolnik, M. C. Garnett, L. Illum, S. S. Davis, S. M. King, R. K. Heenan, S. C. Purkiss, R. J. Barlow, P. R. Gellert, C. Washington, Core-shell structure of PLA-PEG nanoparticles used for drug delivery. Langmuir 19, 8428-8435 (2003).
30. P. M. Valencia, M. H. Hanewich-Hollatz,W. Gao, F. Karim, R. Langer, R. Karnik, O. C. Farokhzad, Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 32, 6226-6233 (2011).
31. M. C. Bissery, G. Nohynek, G. J. Sanderink, F. Lavelle, Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 6, 339-355, 363-368 (1995).
32. S. Reagan-Shaw, M. Nihal, N. Ahmad, Dose translation from animal to human studies revisited. FASEB J. 22, 659-661 (2008).
33. L. E. Lillie, N. J. Temple, L. Z. Florence, Reference values for young normal Sprague-Dawley rats: Weight gain, hematology and clinical chemistry. Hum. Exp. Toxicol. 15, 612-616 (1996).
34. L. Baranyi, J. Szebeni, S. Savay, M. Bodo, B. Milan, T. B. Bentley, R. Bunger, C. R. Alving, Complement-dependent shock and tissue damage induced by intravenous injection of cholesterol-enriched liposomes in rats. J. Appl. Res. 3, 221-231 (2003).
35. E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
36. Food and Drug Administration, HHS, Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule. Fed. Regist. 73, 40453-40463 (2008).
37. E. G. Chiorean, J. M. Porter, A. E. Foster, A. S. Al Omari, C. A. Yoder, K. L. Fife, R. M. Strother, D. J. Murry, M. Yu, D. R. Jones, C. J. Sweeney, A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin. Cancer Res. 14, 1131-1137 (2008).
38. R. Pazdur, M. E. Royce, G. I. Rodriguez, D. A. Rinaldi, Y. Z. Patt, P. M. Hoff, H. A. Burris, Phase II trial of docetaxel for cholangiocarcinoma. Am. J. Clin. Oncol. 22, 78-81 (1999).
39. M. Ferrari, Cancer nanotechnology: Opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
40. R. A. Petros, J. M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615-627 (2010).
41. R. K. Jain, T. Stylianopoulos, Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664 (2010).
42. D. E. Owens III, N. A. Peppas, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102 (2006).
43. L. Zhang, J. M. Chan, F. X. Gu, J. W. Rhee, A. Z. Wang, A. F. Radovic-Moreno, F. Alexis, R. Langer, O. C. Farokhzad, Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano 2, 1696-1702 (2008).
44. Y. Yamamoto, Y. Nagasaki, Y. Kato, Y. Sugiyama, K. Kataoka, Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J. Control Release 77, 27-38 (2001).
45. H. Cabral, Y. Matsumoto, K. Mizuno, Q. Chen, M. Murakami, M. Kimura, Y. Terada, M. R. Kano, K. Miyazono, M. Uesaka, N. Nishiyama, K. Kataoka, Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 6, 815-823 (2011).
46. E. Blanco, E. A. Bey, C. Khemtong, S. G. Yang, J. Setti-Guthi, H. Chen, C. W. Kessinger, K. A. Carnevale, W. G. Bornmann, D. A. Boothman, J. Gao, b-Lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 70, 3896-3904 (2010).
47. N. Bertrand, J. C. Leroux, The journey of a drug-carrier in the body: An anatomo-physiological perspective. J. Control Release 10.1016/j.jconrel.2011.09. 098 (2011).
48. K. K. Jain, Advances in the field of nanooncology. BMC Med. 8, 83 (2010).